The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Secondary Hyperparathyroidism Treatment-Global Market Insights and Sales Trends 2024
Synopsis
Secondary hyperparathyroidism refers to the excessive secretion of parathyroid hormone by the parathyroid glands in response to hypocalcemia and associated hyperplasia of the glands.
The global Secondary Hyperparathyroidism Treatment market size is expected to reach US$ 4471.4 million by 2029, growing at a CAGR of 5.1% from 2023 to 2029. The market is mainly driven by the significant applications of Secondary Hyperparathyroidism Treatment in various end use industries. The expanding demands from the Hospital Pharmacies and Retail Pharmacies, are propelling Secondary Hyperparathyroidism Treatment market. Surgery, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Drugs segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Secondary Hyperparathyroidism Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Secondary Hyperparathyroidism Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Secondary Hyperparathyroidism Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Secondary Hyperparathyroidism Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Secondary Hyperparathyroidism Treatment covered in this report include Amgen, OPKO Health, AbbVie, Astellas Pharma, Roche, KAI Pharmaceuticals, Kyowa Hakko Kirin, Leo Pharma and Takeda, etc.
The global Secondary Hyperparathyroidism Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Amgen
OPKO Health
AbbVie
Astellas Pharma
Roche
KAI Pharmaceuticals
Kyowa Hakko Kirin
Leo Pharma
Takeda
Sanofi
Deltanoid Pharmaceuticals
Global Secondary Hyperparathyroidism Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Secondary Hyperparathyroidism Treatment market, Segment by Type:
Surgery
Drugs
Vitamin D
Calcimimetics
Phosphate Binders
Global Secondary Hyperparathyroidism Treatment market, by Application
Hospital Pharmacies
Retail Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Secondary Hyperparathyroidism Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Secondary hyperparathyroidism refers to the excessive secretion of parathyroid hormone by the parathyroid glands in response to hypocalcemia and associated hyperplasia of the glands.
The global Secondary Hyperparathyroidism Treatment market size is expected to reach US$ 4471.4 million by 2029, growing at a CAGR of 5.1% from 2023 to 2029. The market is mainly driven by the significant applications of Secondary Hyperparathyroidism Treatment in various end use industries. The expanding demands from the Hospital Pharmacies and Retail Pharmacies, are propelling Secondary Hyperparathyroidism Treatment market. Surgery, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Drugs segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Secondary Hyperparathyroidism Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Secondary Hyperparathyroidism Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Secondary Hyperparathyroidism Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Secondary Hyperparathyroidism Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Secondary Hyperparathyroidism Treatment covered in this report include Amgen, OPKO Health, AbbVie, Astellas Pharma, Roche, KAI Pharmaceuticals, Kyowa Hakko Kirin, Leo Pharma and Takeda, etc.
The global Secondary Hyperparathyroidism Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Amgen
OPKO Health
AbbVie
Astellas Pharma
Roche
KAI Pharmaceuticals
Kyowa Hakko Kirin
Leo Pharma
Takeda
Sanofi
Deltanoid Pharmaceuticals
Global Secondary Hyperparathyroidism Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Secondary Hyperparathyroidism Treatment market, Segment by Type:
Surgery
Drugs
Vitamin D
Calcimimetics
Phosphate Binders
Global Secondary Hyperparathyroidism Treatment market, by Application
Hospital Pharmacies
Retail Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Secondary Hyperparathyroidism Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Secondary Hyperparathyroidism Treatment
1.1 Secondary Hyperparathyroidism Treatment Market Overview
1.1.1 Secondary Hyperparathyroidism Treatment Product Scope
1.1.2 Secondary Hyperparathyroidism Treatment Market Status and Outlook
1.2 Global Secondary Hyperparathyroidism Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Secondary Hyperparathyroidism Treatment Market Size by Region (2018-2029)
1.4 Global Secondary Hyperparathyroidism Treatment Historic Market Size by Region (2018-2023)
1.5 Global Secondary Hyperparathyroidism Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Secondary Hyperparathyroidism Treatment Market Size (2018-2029)
1.6.1 North America Secondary Hyperparathyroidism Treatment Market Size (2018-2029)
1.6.2 Europe Secondary Hyperparathyroidism Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size (2018-2029)
1.6.4 Latin America Secondary Hyperparathyroidism Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size (2018-2029)
2 Secondary Hyperparathyroidism Treatment Market by Type
2.1 Introduction
2.1.1 Surgery
2.1.2 Drugs
2.1.3 Vitamin D
2.1.4 Calcimimetics
2.1.5 Phosphate Binders
2.2 Global Secondary Hyperparathyroidism Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Secondary Hyperparathyroidism Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Secondary Hyperparathyroidism Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Secondary Hyperparathyroidism Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Secondary Hyperparathyroidism Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Secondary Hyperparathyroidism Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Secondary Hyperparathyroidism Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Secondary Hyperparathyroidism Treatment Revenue Breakdown by Type (2018-2029)
3 Secondary Hyperparathyroidism Treatment Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacies
3.1.2 Retail Pharmacies
3.2 Global Secondary Hyperparathyroidism Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Secondary Hyperparathyroidism Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Secondary Hyperparathyroidism Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Secondary Hyperparathyroidism Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Secondary Hyperparathyroidism Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Secondary Hyperparathyroidism Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Secondary Hyperparathyroidism Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Secondary Hyperparathyroidism Treatment Revenue Breakdown by Application (2018-2029)
4 Secondary Hyperparathyroidism Treatment Competition Analysis by Players
4.1 Global Secondary Hyperparathyroidism Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Secondary Hyperparathyroidism Treatment as of 2022)
4.3 Date of Key Players Enter into Secondary Hyperparathyroidism Treatment Market
4.4 Global Top Players Secondary Hyperparathyroidism Treatment Headquarters and Area Served
4.5 Key Players Secondary Hyperparathyroidism Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Secondary Hyperparathyroidism Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Amgen
5.1.1 Amgen Profile
5.1.2 Amgen Main Business
5.1.3 Amgen Secondary Hyperparathyroidism Treatment Products, Services and Solutions
5.1.4 Amgen Secondary Hyperparathyroidism Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 Amgen Recent Developments
5.2 OPKO Health
5.2.1 OPKO Health Profile
5.2.2 OPKO Health Main Business
5.2.3 OPKO Health Secondary Hyperparathyroidism Treatment Products, Services and Solutions
5.2.4 OPKO Health Secondary Hyperparathyroidism Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 OPKO Health Recent Developments
5.3 AbbVie
5.3.1 AbbVie Profile
5.3.2 AbbVie Main Business
5.3.3 AbbVie Secondary Hyperparathyroidism Treatment Products, Services and Solutions
5.3.4 AbbVie Secondary Hyperparathyroidism Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Astellas Pharma Recent Developments
5.4 Astellas Pharma
5.4.1 Astellas Pharma Profile
5.4.2 Astellas Pharma Main Business
5.4.3 Astellas Pharma Secondary Hyperparathyroidism Treatment Products, Services and Solutions
5.4.4 Astellas Pharma Secondary Hyperparathyroidism Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Astellas Pharma Recent Developments
5.5 Roche
5.5.1 Roche Profile
5.5.2 Roche Main Business
5.5.3 Roche Secondary Hyperparathyroidism Treatment Products, Services and Solutions
5.5.4 Roche Secondary Hyperparathyroidism Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Roche Recent Developments
5.6 KAI Pharmaceuticals
5.6.1 KAI Pharmaceuticals Profile
5.6.2 KAI Pharmaceuticals Main Business
5.6.3 KAI Pharmaceuticals Secondary Hyperparathyroidism Treatment Products, Services and Solutions
5.6.4 KAI Pharmaceuticals Secondary Hyperparathyroidism Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 KAI Pharmaceuticals Recent Developments
5.7 Kyowa Hakko Kirin
5.7.1 Kyowa Hakko Kirin Profile
5.7.2 Kyowa Hakko Kirin Main Business
5.7.3 Kyowa Hakko Kirin Secondary Hyperparathyroidism Treatment Products, Services and Solutions
5.7.4 Kyowa Hakko Kirin Secondary Hyperparathyroidism Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 Kyowa Hakko Kirin Recent Developments
5.8 Leo Pharma
5.8.1 Leo Pharma Profile
5.8.2 Leo Pharma Main Business
5.8.3 Leo Pharma Secondary Hyperparathyroidism Treatment Products, Services and Solutions
5.8.4 Leo Pharma Secondary Hyperparathyroidism Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 Leo Pharma Recent Developments
5.9 Takeda
5.9.1 Takeda Profile
5.9.2 Takeda Main Business
5.9.3 Takeda Secondary Hyperparathyroidism Treatment Products, Services and Solutions
5.9.4 Takeda Secondary Hyperparathyroidism Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 Takeda Recent Developments
5.10 Sanofi
5.10.1 Sanofi Profile
5.10.2 Sanofi Main Business
5.10.3 Sanofi Secondary Hyperparathyroidism Treatment Products, Services and Solutions
5.10.4 Sanofi Secondary Hyperparathyroidism Treatment Revenue (US$ Million) & (2018-2023)
5.10.5 Sanofi Recent Developments
5.11 Deltanoid Pharmaceuticals
5.11.1 Deltanoid Pharmaceuticals Profile
5.11.2 Deltanoid Pharmaceuticals Main Business
5.11.3 Deltanoid Pharmaceuticals Secondary Hyperparathyroidism Treatment Products, Services and Solutions
5.11.4 Deltanoid Pharmaceuticals Secondary Hyperparathyroidism Treatment Revenue (US$ Million) & (2018-2023)
5.11.5 Deltanoid Pharmaceuticals Recent Developments
6 North America
6.1 North America Secondary Hyperparathyroidism Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Secondary Hyperparathyroidism Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Secondary Hyperparathyroidism Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Secondary Hyperparathyroidism Treatment Market Dynamics
11.1 Secondary Hyperparathyroidism Treatment Industry Trends
11.2 Secondary Hyperparathyroidism Treatment Market Drivers
11.3 Secondary Hyperparathyroidism Treatment Market Challenges
11.4 Secondary Hyperparathyroidism Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
